Cerus (CERS) Debt-to-Asset : 0.48 (As of Mar. 2025)

View and export this data going back to 1997. Start your Free Trial

What is Cerus Debt-to-Asset?

Cerus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $22.6 Mil. Cerus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $76.8 Mil. Cerus's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was $206.8 Mil. Cerus's debt to asset for the quarter that ended in Mar. 2025 was 0.48.

Cerus Debt-to-Asset Historical Data

The historical data trend for Cerus's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Debt-to-Asset Chart

Cerus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.30

0.37

0.40

0.49

Cerus Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial															0.53	0.53	0.52	0.49	0.48

Competitive Comparison of Cerus's Debt-to-Asset

For the Medical Devices subindustry, Cerus's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cerus's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cerus's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Cerus Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cerus's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(21.572	+	76.525)	/	200.917
	=	0.49

Cerus's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(22.629	+	76.817)	/	206.776
	=	0.48

Cerus (NAS:CERS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cerus Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cerus's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

CU2:Germany CU2:Germany

Address

1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520

Website

https://www.cerus.com

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Executives

Chrystal Menard	officer: Chief Legal Officer	C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Kevin Dennis Green	officer: Chief Accounting Officer	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin	officer: Chief Medical Officer	15 WHITE PINE ROAD, NEWTON MA 02464
Vivek K Jayaraman	officer: Chief Commercial Officer	3910 BRICKWAY BLVD, SANTA ROSA CA 95403
William Mariner Greenman	officer: President, Cerus Europe	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Hua Shan	director	C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Jami K Nachtsheim	director
Frank Witney	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Laurence M Corash	director	C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
Carol Moore	officer: SR. V.P. Regulatory, Clinical	C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Ann Lucena	director	C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Gail Schulze	director	3451 WELLS ROAD, MALVERN PA 19355
Timothy B Anderson	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015